Invited reviews: a new addition to Menopause Isaac Schiff, MD 244 Risk of first-time heart disease higher for hormone therapy users with metabolic syndrome
Results of this study show that one-third of women with vasomotor symptoms rapidly experience recurrence of their symptoms to pre-treatment levels after they stop taking the SSRI escitalopram for treatment of vasomotor symptoms. Those with pre-treatment insomnia and those with a weaker response to escitalopram may be at greatest risk for symptom relapse after treatment discontinuation.
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Racial differences in perception of healthy body weight in midlife women: results from the Do Stage Transitions Result in Detectable Effects study Semara Thomas, MD, Roberta B. Ness, MD, MPH, Rebecca C. Thurston, PhD, Karen Matthews, PhD, Chung-Chou Chang, PhD, and Rachel Hess, MD, MS In this cohort study of midlife women, although black women in general face a greater threat of morbidity from weight-related chronic diseases, they are more likely to be accepting of their weight at higher BMI's, relative to white women.
274
Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys Thomas B. Clarkson, DVM, Kelly F. Ethun, DVM, PhD, Haiying Chen, MD, PhD, Debbie Golden, BS, Edison Floyd, BS, and Susan E. Appt, DVM Conjugated equine estrogens (CEE) markedly inhibited the progression of both coronary and iliac artery atherosclerosis of postmenopausal monkeys fed a moderately atherogenic diet. Bazedoxifene had no adverse effects on atherosclerosis but attenuated the atheroprotective effects of CEE.
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Increased long-term recreational physical activity is associated with older age at natural menopause among heavy smokers: the California Teachers Study Aina Emaus, MD, Christina Dieli-Conwright, PhD, Xinxin Xu, MS, James V. Lacey Jr, PhD, Sue A. Ingles, DrPH, Peggy Reynolds, PhD, MPH, Leslie Bernstein, PhD, and Katherine D. Henderson, PhD The determinants of age at natural menopause, including physical activity, may differ by smoking status. This study identified a number of differences in symptoms at midlife and may help healthcare professionals better appreciate the diversity of menopausal experiences and support the development of appropriate care strategies.
C O N T E N T S
(continued) Modulation of higher-primate adrenal androgen secretion with estrogen-alone or estrogen-plus-progesterone intervention Alan J. Conley, BVSc, PhD, Frank Z. Stanczyk, PhD, John H. Morrison, PhD, Pawel Borowicz, PhD, Kurt Benirschke, MD, Nancy A. Gee, BAS, and Bill L. Lasley, PhD Previous reports have identified an increase in adrenal androgen production during the menopausal transition for most women but the mechanism is unknown. The current experimental study addresses that issue by demonstrating that intervention with ovarian sex steroids, as hormone therapy regimens, act to modulate both the structure and function of the adrenal cortex in female primates.
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Dehydroepiandrosterone sulfate levels reflect endogenous luteinizing hormone production and response to human chorionic gonadotropin challenge in older female macaque (Macaca fascicularis) Francisco M. Moran, PhD, Jiangang Chen, MD, PhD, Nancy A. Gee, BAS, Pete N. Lohstroh, PhD, and Bill L. Lasley, PhD Recent evidence indicates that adrenal androgen production rises during the menopausal transition. Using the nonhuman primate animal model, the current study demonstrates the ability of the adrenal gland of older macaques to respond to an acute hCG challenge with increased DHEAS production. 
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Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future Thomas B. Clarkson, DVM, Giselle C. Meléndez, MD, and Susan E. Appt, DVM Events that led up to randomized trials evaluating the cardiovascular risk and benefits of hormone therapy and the pathobiological basis for the timing hypothesis are reviewed. The accumulated evidence supports that estrogen administration in the perimenopausal transition or early in menopause are not cardiovascular harmful and, when given for a few years for the treatment of menopausal symptoms, may slow the progression of atherosclerosis.
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